Progenics Pharmaceuticals, Inc. (PGNX)
-NasdaqGS 4.02 
0.15(3.60%) May 21, 4:00PM EDT|After Hours
:
4.02 0.00 (0.00%) May 21, 4:25PM EDT
| Prev Close: | 4.17 |
|---|
| Open: | 4.08 |
|---|
| Bid: | 3.92 x 4800 |
|---|
| Ask: | 4.11 x 1000 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.51 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 4.00 - 4.16 |
|---|
| 52wk Range: | 1.41 - 11.00 |
|---|
| Volume: | 211,164 |
|---|
| Avg Vol (3m): | 474,452 |
|---|
| Market Cap: | 205.06M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.87 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Progenics Pharmaceuticals Added to the NASDAQ Biotechnology IndexGlobeNewswire(Fri, May 17)
- PROGENICS PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, May 17)
- Salix Beats on EarningsZacks(Tue, May 14)
- Did These Healthcare Stocks Miss or Beat Analyst Expectations?at Wall St. Cheat Sheet(Sun, May 12)
- Faruqi & Faruqi, LLP Launches An Investigation Against Progenics Pharmaceuticals, Inc. (PGNX) For Potential Breaches Of Fiduciary Duties By Its Board Of DirectorsBusiness Wire(Fri, May 10)
- Progenics 1Q loss narrows, revenue tops StreetAP(Fri, May 10)
- Progenics Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 10)
- Progenics Pharmaceuticals Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Fri, May 10)
- Progenics Pharmaceuticals Announces First Quarter 2013 Financial ResultsGlobeNewswire(Fri, May 10)
- Q1 2013 Progenics Pharmaceuticals Earnings Release - Before Market OpenCCBN(Fri, May 10)
- PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Fri, May 10)
- Progenics Pharmaceuticals to Host Conference Call to Review First Quarter 2013 Financial Results on May 10GlobeNewswire(Mon, May 6)
- Short Interest Moves 19% Higher For PGNXat TheStreet(Thu, Apr 25)
- Progenics Pharmaceuticals to Present at Needham Healthcare ConferenceGlobeNewswire(Wed, Apr 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 15.14 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.95 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.23 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | -0.18 |
|---|
Business Summary
Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide.
View More